1. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
- Author
-
Weidhaas, Joanne B, Hu, Chen, Komaki, Ritsuko, Masters, Gregory A, Blumenschein, George R, Chang, Joe Y, Lu, Bo, Dicker, Adam P, Bogart, Jeffrey A, Garces, Yolanda I, Narayan, Samir, Robinson, Clifford G, Kavadi, Vivek S, Greenberger, Joel S, Koprowski, Christopher D, Welsh, James, Gore, Elizabeth M, MacRae, Robert M, Paulus, Rebecca, and Bradley, Jeffrey D
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Lung ,Clinical Trials and Supportive Activities ,Genetics ,Clinical Research ,Cancer - Abstract
PurposeRTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non-small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617.Experimental designFrom RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran-Mantel-Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value
- Published
- 2023